Data completeness
2/8 — Basic
HYDROMOX R (quinethazone; reserpine) by Pfizer is insulin, including humulin r, is the regulation of glucose metabolism. Approved for glycemic control in adult.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYDROMOX R is an oral tablet combining quinethazone and reserpine for glycemic control in adults. The product regulates glucose metabolism by stimulating peripheral glucose uptake and inhibiting hepatic glucose production. It represents a fixed-dose combination approach to diabetes management.
Pre-Launch
Pre-launch stage suggests small, focused team building go-to-market infrastructure with high autonomy for early-stage strategy roles.
Mechanism of Action
insulin, including HUMULIN R, is the regulation of glucose metabolism. Insulin lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein…
Indications (1)
Career Relevance
Working on HYDROMOX R in pre-launch phase offers early-career visibility and broad responsibility across strategy, regulatory, and go-to-market functions. This stage demands entrepreneurial mindset and cross-functional collaboration as the team builds market positioning in a competitive diabetes space.
Worked on HYDROMOX R at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.